DRF 2519

antidiabetic and hypolipidemic; structure in first source

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Chakrabarti, Ranjan: 1 article (05/2004)
2.	Damarla, Ravi K B: 1 article (05/2004)
3.	Datla, Srinivas R: 1 article (05/2004)
4.	Hiriyan, Jagadheshan: 1 article (05/2004)
5.	Misra, Parimal: 1 article (05/2004)
6.	Premkumar, Mamnoor: 1 article (05/2004)
7.	Rajagopalan, Ramanujam: 1 article (05/2004)
8.	Suresh, Juluri: 1 article (05/2004)
9.	Vikramadithyan, Reeba K: 1 article (05/2004)

1.	Hepatocellular Carcinoma (Hepatoma) 05/03/2004 - "In the in vitro studies, DRF 2519 inhibited the lipid biosynthesis and secretion of apolipoprotein B from human hepatoma (Hep)G2 cells. "
2.	Dyslipidemias (Dyslipidemia) 05/03/2004 - "In insulin-resistant ob/ob mouse model, DRF 2519 showed significant alleviation of insulin resistance and dyslipidemia, which is better than rosiglitazone. "
3.	Insulin Resistance 05/03/2004 - "In insulin-resistant ob/ob mouse model, DRF 2519 showed significant alleviation of insulin resistance and dyslipidemia, which is better than rosiglitazone. "